SEAGULL HEALTH
Your health,We care!
Rezvilutamide Tablets feature low blood-brain barrier permeability and minimal risk of central nervous system toxicity, along with favorable safety profile and convenient oral administration.
AuthenticGuaranteeFast DeliveryPrivacy On June 29, 2022, the National Medical Products Administration (NMPA) granted conditional approval for the marketing of Revelumide Tablets for the treatment of patients with high‑volume metastatic hormone‑sensitive prostate cancer (mHSPC).
On June 30, 2022, the National Medical Products Administration (NMPA) approved the market launch of Revelumide Tablets (brand name: Airuien), a Class ···【Read More】
Update: 25 Feb,2026Source: Haiou HealthViews: 75
Copyright 2024 @ haiouhealth.com All right reserved SEAGULL HEALTH
